Adaptimmune Therapeutics plc (ADAP) Financials
ADAP Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 282.6 million | 243.1 million |
2023-09-30 | 296.6 million | 208.5 million |
2023-06-30 | 343.0 million | 216.3 million |
2023-03-31 | 288.1 million | 204.2 million |
ADAP Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -15.5 million | 3.1 million |
2023-09-30 | -45.4 million | 3.2 million |
2023-06-30 | -45.0 million | 3.8 million |
2023-03-31 | -39.8 million | 1.7 million |
ADAP Net Income
No data available :(
ADAP Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 146.9 million | - | 25.2 million |
2023-09-30 | 161.7 million | - | 25.6 million |
2023-06-30 | 204.7 million | - | 26.3 million |
2023-03-31 | 165.6 million | - | 22.8 million |
ADAP Shares Outstanding
ADAP Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 828016 | 37.2 million | 16.9 million | 2.7 million |
2023-09-30 | 289000 | 37.8 million | 16.2 million | - |
2023-06-30 | 1.2 million | 30.0 million | 20.1 million | - |
2023-03-31 | 2.5 million | 25.5 million | 20.4 million | - |
ADAP Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 233009 | 2.9 million |
2023-09-30 | 7.3 million | 2.9 million |
2023-06-30 | 5.1 million | 2.2 million |
2023-03-31 | 47.6 million | 1.9 million |
ADAP
Price: $1.18
52 week price:
Earnings Per Share: -0.54 USD
P/E Ratio: -2.30
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 237100
Ebitda: 858000Market Capitalization: 318.4 million